Publications by authors named "Lucio Catalano"

Claim this Profile
C
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, Vincenzo Pavone, Salvatore Palmieri, Lucio Catalano

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Rossella Iula, Danilo De Novellis, Fabio Trastulli, Roberta Della Pepa, Raffaele Fontana, Lucio Catalano

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Lucio Catalano

Front Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Italian guidelines on management of persons with multimorbidity and polypharmacy.
Graziano Onder, Davide Liborio Vetrano, Katie Palmer, Caterina Trevisan, Laura Amato, Lucio Catalano

Aging Clin Exp Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Lucio Catalano

Eur J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Lucio Catalano

Lancet Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia.
Claudio Cerchione, Giovanni Martinelli, Silvana Pedatella, Mauro De Nisco, Novella Pugliese, Lucio Catalano

Anticancer Drugs· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma.
Rosa Fonti, Sara Pellegrino, Lucio Catalano, Fabrizio Pane, Silvana Del Vecchio

Ann Hematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support.
Claudio Cerchione, Amalia De Renzo, Davide Nappi, Maria Di Perna, Roberta Della Pepa, Lucio Catalano

Support Care Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, Antonietta Falcone, Maria Teresa Petrucci, Lucio Catalano

Ann Hematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, Massimo Offidani, Roberto Ria, Lucio Catalano

Crit Rev Oncol Hematol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and comfort of domestic bortezomib injection in real-life experience.
Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, Maria Di Perna, Irene Zacheo, Lucio Catalano

Support Care Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple myeloma and macro creatine kinase type 1: the first case report.
Angela Ombrato, Antonio Valerio Manzi, Daniela Palmieri, Katia Ferrara, Lucio Catalano

Clin Chem Lab Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.
Claudio Cerchione, Davide Nappi, Anna E Pareto, Alessandra Romano, Vincenzo Martinelli, Lucio Catalano

Anticancer Drugs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Claudio Cerchione, Giuseppe Cerciello, Simona Avilia, Roberta Della Pepa, Novella Pugliese, Lucio Catalano

Blood Transfus· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series.
Elena Cantone, Antonella Miriam Di Lullo, Luana Marano, Elia Guadagno, Gelsomina Mansueto, Lucio Catalano

J Med Case Rep· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.
Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Ilaria Migliaccio, Lucio Catalano

Clin Case Rep· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Claudio Cerchione, Amalia De Renzo, Maria Di Perna, Roberta Della Pepa, Novella Pugliese, Lucio Catalano

Support Care Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone.
Claudio Cerchione, Lucio Catalano, Ilaria Peluso, Davide Nappi, Maria Di Perna

Support Care Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.
Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Anna Emanuele Pareto, Lucio Catalano

Case Rep Hematol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study.
Vincenzo Schiano-Lomoriello, Maurizio Galderisi, Donato Mele, Roberta Esposito, Giuseppe Cerciello, Lucio Catalano

Echocardiography· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.
Claudio Cerchione, Mariano Lucignano, Fabrizio Pane, Lucio Catalano

Eur J Haematol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, Concetta Conticello, Lucio Catalano

Lancet Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Rosa Fonti, Leonardo Pace, Claudio Cerchione, Lucio Catalano, Barbara Salvatore

Clin Nucl Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience.
Claudio Cerchione, Lucio Catalano, Anna Emanuele Pareto, Marco Picardi, Fabrizio Pane

Support Care Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis